CetuGEX™

DRUG2 trials

Sponsors

Glycotope GmbH

Conditions

Carcinoma, Squamous Cell of Head and NeckSolid Tumors

Phase 1

CetuGEX™: Phase 1 Study in Cancer Patients

CompletedNCT01222637

Glycotope GmbHSolid Tumors

Start: 2010-08-31End: 2013-10-31Updated: 2021-05-25

Phase 2

CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer

CompletedNCT02052960

Glycotope GmbHCarcinoma, Squamous Cell of Head and Neck

Start: 2014-02-28End: 2017-10-04Updated: 2021-11-02

Related Papers

Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.

Journal of Clinical Oncology2018-02-105 citations

CetuGEX and cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): PK/PD results from the phase II RESGEX study.

Journal of Clinical Oncology2018-02-102 citations